Neoadjuvant gemcitabine/cisplatin plus tislelizumab in resectable muscle-invasive bladder cancer (BGB-A317-2002)
Release date:
2024-08-02
Description:
To further evaluate the role of GC plus anti-PD-1 as neoadjuvant treatment for MIBC, we designed a phase 2 trial integrating (1) cisplatin-based chemotherapy plus tislelizumab; and (2) biomarkers to refine future patient selection for this approach.
For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.
You need to install the Aspera Connect plugin before uploading your files. If you dont have Aspera Connect plugin installed in your computer, please Download Aspera Connectand install it first.
[path/to/ascp]: Microsoft Windows: C:\Program Files\Aspera\Aspera Connect\bin\ascp.exe or
c:\users\[username]\AppData\Local\Programs\Aspera\Aspera Connect\bin\ascp.exe
Mac OS X: /Applications/Aspera/Connect.app/Contents/Resources/ascp (for admin's installation) or
/Users/[username]/Applications/Aspera/Connect.app/Contents/Resources/ascp (for non-admin's installation)
Linux: /opt/aspera/bin/ascp or
/home/[username]/aspera/connect/bin/ascp
[path/to/key/file] must be an absolute path, e.g.: /home/keys/aspera.openssh
[path/to/folder/containing/files] needs to specify the local folder that contains all the files to upload.
HRA006086.xlsx